prIME Masterclass in Neuroendocrine Tumors

Not a member of My prIME? Join now for instant access.

To apply for a travel grant, click on the Register Now button.

Meeting Overview

Engage with experts in the field of neuroendocrine tumors (NETs) by joining this highly interactive 1.5-day live meeting. Our experts will provide a comprehensive update on the management of NETs, focusing on recent developments in imaging and therapeutic options by using the following strategies:

  • Didactic presentations
  • Breakout interactive clinical case presentations
  • “Beat the Experts” NETs quiz
  • Panel and audience discussions

Date and Location

Friday and Saturday
10 – 11 November 2017

De Koepelkerk
Renaissance Amsterdam Hotel
Kattengat 1
Amsterdam, the Netherlands



Friday and Saturday
10 – 11 November 2017



Amsterdam, the Netherlands



7.0 European CME Credits

Friday, 10 November—Day 1

10.30 Registration
12.00 Lunch
 Plenary Session I
13.00 Welcome and introduction
Dermot O’Toole, MD, FRCPI, and Philippe Ruszniewski, MD
13.15 Epidemiology and prognosis of NETs
Ulrich-Frank Pape, MD
13.45 Q & A
13.55 Pathology of NETs in 2017
Jean-Yves Scoazec, MD, PhD
14.25 Q & A
14.35 Locoregional treatments
Marnix Lam, MD, PhD
15.05 Q & A
15.15 Wait-and-see management for gastroenteropancreatic (GEP) NETs: The surgical and medical perspectives
Andreas Pascher, MD, PhD, and Wouter de Herder, MD, PhD
15.45 Q & A
15.55 Afternoon tea break
 Parallel Break-Out Sessions I
A Exploring treatment options for patients with metastatic GEP NETs
Jaume Capdevila, MD, PhD
B Pulmonary NETs: Similarities and differences in management of GEP NETs
Marianne Pavel, MD
C Safe delivery of targeted treatments for NETs
Matthias Weber, MD
D Medical complications of NETs
Philippe Ruszniewski, MD
17.00 Break to move to Parallel Break-Out Session II
 Parallel Break-Out Sessions II
A Exploring treatment options for patients with metastatic GEP NETs
Jaume Capdevila, MD, PhD
B Pulmonary NETs: Similarities and differences in management of GEP NETs
Marianne Pavel, MD
C Safe delivery of targeted treatments for NETs
Matthias Weber, MD
D Medical complications of NETs
Philippe Ruszniewski, MD
17.55 End of day 1
20.00 Dinner

Saturday, 11 November—Day 2

08.00 Breakfast
09.00 Introduction to day 2
 Plenary Session II
09.10 Immunotherapy for cancer: Implications for future NET management
Rolf Kiessling, MD, PhD
09.40 Q & A
09.50 Peptide receptor radionuclide radiotherapy—How, why, and when?
Richard Baum, MD, PhD
10.20 Q & A
10.30 Coffee break
11.00 Imaging of NETs: Toward a one-stop shop
Prakash Manoharan, MBChB, MRCP, FRCR
11.30 Q & A
11.40 Meaningful patient advocacy
Teodora Kolarova
12.00 Q & A
12.10 Lunch
 Plenary Session III
13.10 “Beat the Experts” NETs quiz
Dermot O’Toole, MD, FRCPI, and Philippe Ruszniewski, MD
13.30 Emerging developments in NETs
13.30 Biology and molecular pathology
Vincenzo Corbo, PhD
13.50 Imaging
Maxime Ronot, MD, PhD
14.10 Therapeutic developments
Dermot O’Toole, MD, FRCPI
14.30 Hot topics panel discussion
Co-Chairs and Faculty
14.50 Prizes and meeting prIME Points™
15.05 Afternoon tea break and adjourn


  • Dermot O’Toole, MD, FRCPISt Vincent’s University Hospital
    St James's Hospital
    Trinity College Dublin
    Dublin, Ireland
  • Philippe Ruszniewski, MDParis University
    Beaujon Hospital
    Clichy, France

  • Richard Baum, MD, PhDZentralklinik Bad Berka
    Bad Berka, Germany
  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Vincenzo Corbo, PhDUniversity and Hospital Trust of Verona
    Verona, Italy
  • Wouter de Herder, MD, PhDErasmus MC
    Rotterdam, the Netherlands
  • Rolf Kiessling, MD, PhDKarolinska Institutet
    Stockholm, Sweden
  • Teodora KolarovaInternational Neuroendocrine Cancer Alliance
    Sofia, Bulgaria
  • Marnix Lam, MD, PhDUniversity Medical Center Utrecht
    Utrecht, the Netherlands
  • Prakash Manoharan, MBChB, MRCP, FRCRThe Christie Neuroendocrine Centre of Excellence
    Manchester, United Kingdom
  • Ulrich-Frank Pape, MDCharité University Hospital
    Berlin, Germany
  • Andreas Pascher, MD, PhDCharité University Hospital
    Berlin, Germany
  • Marianne Pavel, MDUniversity Hospital Erlangen
    Erlangen, Germany
  • Maxime Ronot, MD, PhDBeaujon University Hospital
    Clichy, France
  • Jean-Yves Scoazec, MD, PhDGustave Roussy
    Villejuif, France
  • Matthias Weber, MDJohannes Gutenberg University Mainz
    Mainz, Germany

This educational activity is designed for European medical oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved in the management of patients with NETs.

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, natural history, and pathophysiology of NETs
  • Define the role of modern functional imaging technologies in the evaluation of NETs
  • Describe the various treatment pathways for functioning and non-functioning NETs
  • Evaluate the various therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs

This educational activity is supported by Ipsen.

Continuing Education

prIME Masterclass in Neuroendocrine Tumors held in Amsterdam, Netherlands on 10/11/2017-11/11/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

prIME Masterclass in Neuroendocrine Tumors has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 8 category 1 (external) CPD credit(s).

Good CME Practice



This activity is provided by prIME Oncology.

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.